Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2029-12-30
Target enrollment:
Participant gender:
Summary
The combination of neoadjuvant immunotherapy plus chemotherapy has recently been shown to
improve survival outcome compared to chemotherapy alone and was recently approved for
resectable non-small cell lung cancer (NSCLC). Despite so, recurrence risk of NSCLC after
surgical resection remains high. Sacituzumab govitecan, a novel antibody drug conjugate, was
demonstrated to be clinically active in metastatic NSCLC. This study aims to study the
clinical efficacy of sacituzumab govitecan plus immunotherapy in resectable NSCLC. This is a
open-label, single arm, multicentre, phase II study. Patients with EGFR/ALK negative, stage
II-III (AJCC 8th edition), resectable NSCLC are eligible and will receive 4 cycles of
neoadjuvant pembrolizumab plus sacituzumab govitecan, followed by surgical resection of
tumour, and then 13 cycles of maintenance pembrolizumab.